← All trials
NCT03162055
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 25, 2017
- Primary completion
- Aug 30, 2018
- Completion date
- Aug 30, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- Cognizant Technology SolutionCollaborator
- Corporate Translations IncCollaborator
- ParexelCollaborator
- ERT ClinicalCollaborator
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.